Skip to main content

Table 2 Number of patients who had an adverse event in any category, and number of adverse events by category, Main part

From: Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study

 

AZD8848 (n = 26)

Placebo (n = 25)

All (n = 51)

Patients with an AEa, n (%)

 Any AEs

22 (85)

22 (88)

44 (86)

 Fatal SAEs

0

0

0

 Non-fatal SAEs

0

1 (4)

1 (2)

 DAEsb

4 (15)

2 (8)

6 (12)

 Other significant adverse events

0

0

0

Total number of adverse eventsc, n

 Any adverse events

84

94

178

Maximum intensity

 Mild

65

70

135

 Moderate

16

23

39

 Severe

3

1

4

Maximum AEs/patient

8

9

9

Causally related AEsd

22

11

33

SAEs (fatal and non-fatal)

0

1

1

Causally related SAEs (fatal and non-fatal)d

0

1

1

DAEs

9

2

11

Other significant adverse events

0

0

0

  1. aPatients with multiple events in the same category are counted once in each category; b discontinuation of investigational product/study due to AEs; c multiple events with the same preferred term are counted once for each patient and category; d as assessed by the investigator
  2. Abbreviations: DAEs adverse events leading to treatment discontinuation, SAEs serious adverse events